Ovarian Cancer
Metastatic Ovarian Carcinoma
Female, 57 years
Patient Internal ID: 273984642
ICD-10 code
C56 Malignant Neoplasm of Ovary
Diagnosis (Incl. Metastases/Stage) and Year
March 2010
Ovarian Carcinoma pT3aNxM0 G2 stage 3A, BRCA (-). Disease progression in 2012, Metastasis in Peritoneum, Disease progression in 2021 – Metastatic Lymph nodes in Rectal Region.
Previous Treatment
Surgery, Radiation Therapy, Chemotherapy (Carboplatin and Cyclophosphamide), Surgery, Intraperitoneal Chemotherapy (Paclitaxel and Cisplatin), Surgery, Chemotherapy (Paclitaxel and Cisplatin), Surgery (HIPEC), Chemotherapy (Carboplatin and Gemcitabine), Chemotherapy (Liposomal Doxorubicin and Carboplatin), Chemotherapy (Paclitaxel and Carboplatin), Chemotherapy (Paclitaxel and Carboplatin), Chemotherapy (Topotecan), Radiation Therapy, Chemotherapy (Vinorelbine).
Prognosis and Survival Expectation
The Metastatic Ovarian Cancer prognosis remains poor, with a median survival of ~32 months from diagnosis. The average relative 5-year survival rate for Distant Spread Ovarian Cancer is about 31%.
Treatment Provided
Autologous DCV (8 doses) and CIK (4 doses) over a period of 8 months. Additionally, the patient received Umbilical Cord Blood Derived NK cells (9 doses).
Patient Survival/Condition and Year
Date of Review: 14/12/2023
The patient has survived for 11 years since the disease progression and continues to receive Chemotherapy. It can be concluded that the addition of Immunotherapy, alongside Surgery, Chemotherapy and Radiation Therapy, has extended patient survival by an estimate of around 8 years so far.
